You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 利好疊加 和黃醫藥(0013.HK)反彈近7%
格隆匯 11-02 10:55
格隆匯11月2日丨昨日創新低的和黃醫藥(0013.HK)反彈近7%,報48.05港元,總市值416億港元。公司宣佈與阿斯利康啟動SAMETA研究。SAMETA是一項全球III期臨牀試驗,與阿斯利康的PD-L1抑制劑英飛凡聯合療法,用於治療MET驅動的乳頭狀腎細胞癌患者,首名患者已於今年10月28日接受首次給藥治療。另外,公司日前啟動一項HMPL-523治療免疫性血小板減少症的中國III期研究。值得一提的是,公司Surufatinib已經在中國上市,用於治療神經內分泌腫瘤患者,並計劃於22年上半年在歐洲和美國上市,中金相信將加速產品銷售的提升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account